Compare KOPN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | LCTX |
|---|---|---|
| Founded | 1984 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 393.9M |
| IPO Year | 1992 | N/A |
| Metric | KOPN | LCTX |
|---|---|---|
| Price | $2.42 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.25 | $4.25 |
| AVG Volume (30 Days) | ★ 3.6M | 2.4M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,602,295.00 | $10,816,000.00 |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $29.71 | $176.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.02 | ★ 24.05 |
| 52 Week Low | $0.71 | $0.37 |
| 52 Week High | $4.16 | $2.09 |
| Indicator | KOPN | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 50.42 |
| Support Level | $2.24 | $1.66 |
| Resistance Level | $2.50 | $1.99 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 22.22 | 27.27 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.